|
|
 |
|
Viewing report
|
|
|
|
Mexico Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, Feb 2009, Pages: 77
Mexico Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Mexico's pharmaceuticals and healthcare industry.
For this Q109 update of Mexico’s Pharmaceutical & Healthcare Report, BMI has extended the forecasts through to 2013, when medicine sales will have reached US$25.8bn. The main drivers of market growth are a rapidly expanding economy; improving regulations; a greater uptake of patented products; an increasing disease burden; and more access to health insurance.
The reputation of Mexico’s pricing system received a boost in August 2008. Several pharmaceutical companies including Merck Sharp & Dohme (MSD), Boeringer Ingleheim and GlaxoSmithKline (GSK) reduced the price of their antiretroviral (ARV) drugs following negotiations with the government. The health ministry expects to save over US$31mn a year.
Mexico's pharmaceutical association, AFM, issued a statement in August 2008, declaring that the government's decision to abolish the requirement for pharmaceutical companies to have a manufacturing plant in Mexico in order to sell drugs could have 'unforeseeable negative consequences'. The decision, aimed at boosting competition in the generics drug sector in order to bring down perceived high drug prices, endangers patients and threatens local industry according to the AFM.
According to local reports, diabetes accounts for 34% of Mexico’s public health insurance spending, and local experts predict that, on current trends, the number of diabetics in Mexico could rise by a third by 2010. Moreover, around 35% of Mexico’s 6.5mn diabetics are reported to be unaware that they have the disease.
The provision of healthcare facilities is lacking in Mexico. According to the Pan American Health Organization (PAHO), there are 1.6 beds per 1,000 population in the country, which compares unfavourably with Uruguay (2.9), Brazil (2.4), Chile (2.3) and Ecuador (1.7).
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Mexico Pharmaceuticals and Healthcare Report Q3 2008
Mexico Pharmaceuticals and Healthcare Report Q4 2008
Mexico Pharmaceuticals and Healthcare Report Q2 2009
The Pharmaceutical Market: Mexico
Mexico Pharmaceuticals and Healthcare Report Q2 2008
Mexico Pharmaceuticals and Healthcare Report Q1 2008
Emerging pharmaceutical markets Argentina and Mexico
Mexico Insurance Report Q4 2008
Pharmaceutical Industry in Mexico
Executive Report on Strategies in Mexico
Australia Pharmaceuticals and Healthcare Report Q3 2008
Nigeria Pharmaceuticals and Healthcare Report Q3 2008
|
|
|
|
